Biomarin Pharmaceutical Inc (NAS:BMRN)
$ 67.32 0.25 (0.37%) Market Cap: 12.83 Bil Enterprise Value: 12.46 Bil PE Ratio: 40.31 PB Ratio: 2.37 GF Score: 69/100

Q1 2019 Biomarin Pharmaceutical Inc Earnings Call Transcript

Apr 25, 2019 / 08:30PM GMT
Release Date Price: $85.31 (-0.21%)
Operator

Welcome to the BioMarin First Quarter and Full Year 2018 Financial Results Conference Call.

Hosting the conference call today from BioMarin is Traci McCarty, Vice President of Investor Relations. Please go ahead, Traci.

Traci McCarty
BioMarin Pharmaceutical Inc. - VP of IR

Thank you, Mary. To remind you, this nonconfidential presentations contains forward-looking statements about the business prospects of Biomarin Pharmaceutical Inc. including expectations regarding BioMarin's financial performance, its commercial products and potential future products and different areas of therapeutic research and development. Results may differ materially depending on the progress of Biomarin's product programs, actions of regulatory authority, availability of capital, future actions in the pharmaceutical market and developments by competitors, and those factors detailed in Biomarin's filings with the Securities and Exchange Commission such as 10-Q, 10-K and 8-K report.

On the call from BioMarin's management team today are J.J. Bienaimé, Chairman and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot